admin – Page 7704 – Get News Story

TradeManifest Unveils Innovative Algorithm for Immediate Market Reversal Signals

TradeManifest, a leading name in real-time algorithmic market data analysis, is excited to announce the launch of a new, state-of-the-art algorithm designed to offer traders immediate buy and sell signals during pivotal market shifts. This innovative algorithm extends its reach across multiple trading platforms, including stocks, futures, forex, options, cryptocurrencies, ETFs, and more. Integrated with major global exchanges, it provides traders with extensive access and opportunities in the trading arena.

At the heart of TradeManifest is a commitment to building a highly profitable trading system, and this new algorithm is a testament to that commitment. Utilizing advanced pattern recognition and noise reduction techniques, it enables the early identification of market trends, offering traders timely predictive signals for buying and selling, thus enhancing their competitive edge.

CEO Matias Johnston shares his enthusiasm: “Our goal at TradeManifest is to empower traders with effective strategies leading to exceptional profitability. The introduction of this algorithm marks a pivotal change in the trading industry and sets new standards in algorithmic trading. We’re confident that this enhancement will substantially increase our users’ average net profits.”

The algorithm, incorporated into TradeManifest’s exclusive market scanner, has undergone extensive testing to ensure its accuracy in identifying optimal trading signals. Long-time user Jeremy Young praises the new development, stating, “This algorithm has transformed my trading approach, providing precise signals that significantly boost my profits.” Grayson Campbell, another satisfied trader, adds, “TradeManifest’s adaptive strategies and tools have been indispensable in navigating market volatility. This update has elevated my trading strategy.”

In keeping with TradeManifest’s dedication to customer satisfaction, the update is being offered at no additional cost to existing customers, fulfilling the company’s promise of value. With a deep understanding of market dynamics, securities trading, and comprehensive algorithm research, TradeManifest is leading the charge in providing the most profitable trading systems, empowering traders to achieve substantial financial gains.

Continuing to innovate and excel, TradeManifest is reshaping the approach traders take to market analysis and decision-making, maintaining its position at the forefront of the trading industry.

About TradeManifest

As an innovator in advanced trading solutions, TradeManifest specializes in sophisticated algorithms that analyze real-time market data. Led by a team of experts, TradeManifest’s mission is to equip traders with top-tier tools and strategies, ensuring profitable ventures in the dynamic trading environment. For more information, visit https://www.trademanifest.com.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: TradeManifest Inc.
Contact Person: Lukas Butler
Email: Send Email
Country: United States
Website: https://www.trademanifest.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: TradeManifest Unveils Innovative Algorithm for Immediate Market Reversal Signals

Crohn’s Disease Pipeline, Emerging Drugs, Clinical Trials, FDA Approvals 2024 (Updated)

DelveInsight’s, “Crohn’s Disease Pipeline Insight 2024” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the Crohn’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Crohn’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Crohn’s Disease Pipeline Report

DelveInsight’s Crohn’s Disease pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Crohn’s Disease treatment.
The leading companies working in the Crohn’s Disease Market include Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.
Promising Crohn’s Disease Pipeline Therapies in the various stages of development include Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.
January 2024: Pfizer announced a study of Phase 3 clinical trials for Etrasimod. This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn’s disease (CD) who are refractory or intolerant to at least 1 of the current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics).
January 2024: AstraZeneca announced a study of Phase 1 clinical trials for AZD7798. This study will assess the safety, tolerability, immunogenicity, and pharmacokinetics (PK), and explore the pharmacodynamics (PD) following single ascending dose administration and repeat dose administration in healthy subjects and patients with Crohn’s disease.
January 2024: AbbVie announced a study of Phase 3 clinical trials for Risankizumab SC. A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Risankizumab Subcutaneous Induction Treatment in Subjects With Moderately to Severely Active Crohn’s Disease.
January 2024: Prometheus Biosciences Inc., announced a study of Phase 2 clinical trials for PRA023 IV. The purpose of this study is to assess the safety and efficacy of PRA023 in participants with moderately to severely active Crohn’s Disease.

Request a sample and discover the recent advances in Crohn’s Disease Treatment Drugs @ Crohn’s Disease Pipeline Report

In the Crohn’s Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Crohn’s Disease clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Crohn’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Crohn’s Disease Overview

Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract, where inflammation extends all the way through the intestinal wall from mucosa to serosa. It is a relapsing and remitting disease. Initially only a small segment of the gastrointestinal tract may be involved, but Crohn’s disease has the potential to progress extensively.

Find out more about Crohn’s Disease Therapeutics Assessment @ Crohn’s Disease Preclinical and Discovery Stage Products

Crohn’s Disease Emerging Drugs Profile

Guselkumab: Janssen
RHB-104: RedHill Biopharma

Crohn’s Disease Pipeline Therapeutics Assessment

There are approx. 90+ key companies which are developing the Crohn’s Disease therapies. The Crohn’s Disease companies which have their Crohn’s Disease drug candidates in the most advanced stage, i.e. Phase III include, Janseen.

DelveInsight’s Crohn’s Disease pipeline report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Intramuscular
Topical.
Molecule Type

Crohn’s Disease Pipeline Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Learn more about the emerging Crohn’s Disease Pipeline Therapies @ Crohn’s Disease Clinical Trials Assessment

Scope of the Crohn’s Disease Pipeline Report

Coverage- Global
Crohn’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Crohn’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Crohn’s Disease Companies- Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, and others.
Crohn’s Disease Pipeline Therapies- Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.

Dive deep into rich insights for new drugs for Crohn’s Disease Treatment, Visit @ Crohn’s Disease Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Crohn’s Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Crohn’s Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Crohn’s Disease Collaboration Deals
Late Stage Products (Registered)
Infliximab biosimilar: Amgen
Drug profiles in the detailed report…..
Late Stage Products (Phase III)
Guselkumab: Janssen
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
ABX464: Pfizer
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Mocravimod: Priothera
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
IMU-856: Immunic
Drug profiles in the detailed report…..
Preclinical Stage Products
INV-88: Innovimmune Biotherapeutics
Drug profiles in the detailed report…..
Discovery Stage Products
DNL975: Denali Therapeutics
Inactive Products
Crohn’s Disease Key Companies
Crohn’s Disease Key Products
Crohn’s Disease- Unmet Needs
Crohn’s Disease- Market Drivers and Barriers
Crohn’s Disease- Future Perspectives and Conclusion
Crohn’s Disease Analyst Views
Crohn’s Disease Key Companies
Appendix

For further information on the Crohn’s Disease Pipeline therapeutics, reach out to Crohn’s Disease Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Crohn\’s Disease Pipeline, Emerging Drugs, Clinical Trials, FDA Approvals 2024 (Updated)

Epilepsy Pipeline, Emerging Drugs, Clinical Trials, FDA Approvals 2024 (Updated)

DelveInsight’s, “Epilepsy Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in the Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Epilepsy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Epilepsy Pipeline Report

DelveInsight’s Epilepsy pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Epilepsy treatment.
The leading companies working in the Epilepsy market include UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics, and others.
Promising Epilepsy Pipeline Therapies in the various stages of development include topiramate, Lacosamide, Levetiracetam, UCB0942, Intravenous Carbamazepine (IV CBZ), Diazepam Buccal Film, XEN1101, and others.
January 2024: UCB Biopharma SRL announced a study of Phase 3 clinical trials for Brivaracetam. The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
January 2024: Management of Drug-resistant Epilepsy in Infants and Children: a Real-life Study of the Use of the Ketogenic Diet in France and the KetoCal® Range in Its Maintenance.
January 2024: MedtronicNeuro, the study is designed to evaluate the safety and efficacy of the Visualase MRI-guided laser ablation system for mesial temporal epilepsy (MTLE).

Request a sample and discover the recent advances in Epilepsy Treatment Drugs @ Epilepsy Pipeline Report

The Epilepsy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Epilepsy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Epilepsy clinical trial landscape.

Epilepsy Overview

Epilepsy is one of the most common serious brain conditions, affecting over 50 million people worldwide. Epilepsy is a neurological disorder that is characterized by an enduring predisposition to generate epileptic seizures and the associated cognitive, psychological, and social consequences.

Find out more about Epilepsy Treatment Landscape @ Drugs for Epilepsy Treatment

Epilepsy Emerging Drugs Profile

ZX008 (Fenfluramine Hydrochloride): UCB
Cenobamate: SK Life Science, Inc.
STK-001: Stoke Therapeutics
EPX-100: Epygenix
NRTX-1001: Neurona Therapeutics
BMB-101: Bright Minds Biosciences

Epilepsy Pipeline Therapeutics Assessment

The Epilepsy pipeline report proffers an integral view of the Epilepsy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

DelveInsight’s Epilepsy Pipeline report covers around 90+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Epilepsy Pipeline Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn more about the emerging Epilepsy Pipeline Therapies @ Epilepsy Clinical Trials Assessment

Scope of the Epilepsy Pipeline Report

Coverage- Global
Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Epilepsy Companies- UCB, SK Life Science, Stoke Therapeutics, Xenon Pharmaceuticals, Epygenix, Bright Minds Biosciences, Neurona Therapeutics, Cevevel Therapeutics, PTC Therapeutics, Addex Pharmaceuticals, Equilibre Biopharmaceuticals B.V., ES Therapeutics Australia Pty Ltd, Overseas Pharmaceuticals, Anavex Life Sciences, Eliem Therapeutics, Ovid Therapeutics, CAMP4 Therapeutics, LifeSplice, Virpax Pharmaceuticals, Neuroene Therapeutics, and others.
Epilepsy Pipeline Therapies- topiramate, Lacosamide, Levetiracetam, UCB0942, Intravenous Carbamazepine (IV CBZ), Diazepam Buccal Film, XEN1101, and others.

Dive deep into rich insights for new drugs for Epilepsy Treatment, Visit @ Epilepsy Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Epilepsy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Epilepsy– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
ZX008 (Fenfluramine Hydrochloride): UCB
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
STK-001: Stoke Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
BMB-101: Bright Minds Biosciences
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
NT102: Neuroene Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Epilepsy Key Companies
Epilepsy Key Products
Epilepsy- Unmet Needs
Epilepsy- Market Drivers and Barriers
Epilepsy- Future Perspectives and Conclusion
Epilepsy Analyst Views
Epilepsy Key Companies
Appendix

For further information on the Epilepsy Pipeline therapeutics, reach out to Epilepsy Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epilepsy Pipeline, Emerging Drugs, Clinical Trials, FDA Approvals 2024 (Updated)

Eosinophilic Esophagitis Pipeline, Emerging Drugs, Clinical Trials, FDA Approvals 2024 (Updated)

DelveInsight’s, “Eosinophilic Esophagitis Pipeline Insight 2024” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the Eosinophilic Esophagitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eosinophilic Esophagitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Eosinophilic Esophagitis Pipeline Report

DelveInsight’s Eosinophilic Esophagitis pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Eosinophilic Esophagitis treatment.
The leading companies working in the Eosinophilic Esophagitis Market include AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, Takeda, Dr Falk Pharma, DBV Technologies, Revolo Biotherapeutics, EsoCap, Aqilion, Serpin Pharma, and others.
Promising Eosinophilic Esophagitis Pipeline Therapies in the various stages of development include Tezepelumab, Etrasimod, Reslizumab, Dupilumab, ESO-101, NDX-3315, and others.
January 2024: AstraZeneca announced a study of Phase 3 clinical trials for Tezepelumab. A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).
January 2024: Eliodi Pharmaceuticals announced a study of Phase 3 clinical trials for APT-1011. This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (EoE) followed by a single-arm, open-label extension. This study will evaluate the efficacy and safety of APT-1011 3 mg administered HS (hora somni, at bedtime) for the induction of response to treatment (symptomatic and histologic) over 24 weeks. The open-label extension will continue to evaluate long-term safety in subjects who consent to continue on open-label treatment with APT-1011.
January 2024: Celldex Therapeutics announced a study of Phase 2 clinical trials for barzolvolimab. The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.

Request a sample and discover the recent advances in Eosinophilic Esophagitis Treatment Drugs @ Eosinophilic Esophagitis Pipeline Report

In the Eosinophilic Esophagitis pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Eosinophilic Esophagitis Overview

Eosinophilic Esophagitis (EoE) is a chronic inflammatory condition of the esophagus characterized by the presence of an elevated number of eosinophils, a type of white blood cell, in the lining of the esophagus. Eosinophils are typically associated with allergic responses and immune reactions. In the case of EoE, their accumulation in the esophagus can lead to inflammation, tissue damage, and various symptoms.

Find out more about Eosinophilic Esophagitis Therapeutics Assessment @ Eosinophilic Esophagitis Preclinical and Discovery Stage Products

Eosinophilic Esophagitis Emerging Drugs Profile

APT-1011: Ellodi Pharmaceuticals.

DelveInsight’s Eosinophilic Esophagitis Pipeline Report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Eosinophilic Esophagitis Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous

Eosinophilic Esophagitis Pipeline Products have been categorized under various Molecule types such as

Peptide
Protein
Propylene glycols
Cell Therapy

Eosinophilic Esophagitis Pipeline Therapeutics Assessment

There are approx. 18+ Eosinophilic Esophagitis companies which are developing the Eosinophilic Esophagitis therapies. The Eosinophilic Esophagitis companies which have their Eosinophilic Esophagitis drug candidates in the most advanced stage, i.e. Phase III include, Ellodi Pharmaceuticals.

Learn more about the emerging Eosinophilic Esophagitis Pipeline Therapies @ Eosinophilic Esophagitis Clinical Trials Assessment

Scope of the Eosinophilic Esophagitis Pipeline Report

Coverage- Global
Eosinophilic Esophagitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Eosinophilic Esophagitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Eosinophilic Esophagitis Companies- AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, Takeda, Dr Falk Pharma, DBV Technologies, Revolo Biotherapeutics, EsoCap, Aqilion, Serpin Pharma, and others.
Eosinophilic Esophagitis Pipeline Therapies- Tezepelumab, Etrasimod, Reslizumab, Dupilumab, ESO-101, NDX-3315, and others.

Dive deep into rich insights for new drugs for Eosinophilic Esophagitis Treatment, Visit @ Eosinophilic Esophagitis Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Eosinophilic Esophagitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Eosinophilic Esophagitis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Benralizumab: AstraZeneca
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
IRL201104: Revolo Biotherapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Mometasone: EsoCap
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AQ280: Aqilion
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
SP 16: Serpin Pharma
Drug profiles in the detailed report…..
Inactive Products
Eosinophilic Esophagitis Key Companies
Eosinophilic Esophagitis Key Products
Eosinophilic Esophagitis- Unmet Needs
Eosinophilic Esophagitis- Market Drivers and Barriers
Eosinophilic Esophagitis- Future Perspectives and Conclusion
Eosinophilic Esophagitis Analyst Views
Eosinophilic Esophagitis Key Companies
Appendix

For further information on the Eosinophilic Esophagitis Pipeline therapeutics, reach out to Eosinophilic Esophagitis Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Eosinophilic Esophagitis Pipeline, Emerging Drugs, Clinical Trials, FDA Approvals 2024 (Updated)

SYMDEKO Market Size expected to increase many folds by 2032, reports DelveInsight

[Las Vegas, United States] (25 January 2024) The Latest report, SYMDEKO Market Size, Forecast, and Drug Insight 2032 is published by DelveInsight, a leader in healthcare research firm, providing insights into the SYMDEKO market landscape and market forecast of SYMDEKO up to 2032. This report is now available for review and analysis.

Are you interested in finding out the projected market size of SYMDEKO in 2032? Click @ SYMDEKO Market Size

The SYMDEKO Market Report offers projected sales forecasts for SYMDEKO for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products for Cystic Fibrosis. It also covers analyst views along with market drivers and barriers.

Do you know your drug’s competitive positioning against SYMDEKO? Download Report: SYMDEKO Market Outlook

SYMDEKO is serving as a beacon of hope for the patients suffering from the Cystic Fibrosis.

SYMDEKO falls under the category of medications known as “cystic fibrosis transmembrane conductance regulator (CFTR) modulators.” It consists of two types of tablets: one containing tezacaftor and ivacaftor for the morning dose, and the other containing ivacaftor for the evening dose. Tezacaftor functions as a “CFTR corrector,” enhancing the presence of protein at the cell surface. On the other hand, ivacaftor acts as a “CFTR potentiator,” improving the protein’s functionality once it reaches the cell surface.

The report extensively covers the details and developments related to SYMDEKO, capturing important highlights on the developmental pipeline, regulatory status and special designations of SYMDEKO, route of administration, safety and efficacy details.

SYMDEKO Market Assessment

This report provides a detailed market assessment of SYMDEKO for Cystic Fibrosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

SYMDEKO Clinical Assessment

The report provides the clinical trials information of SYMDEKO for Cystic Fibrosis covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.

SYMDEKO Competitive Landscape

The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the SYMDEKO.

SYMDEKO Market Size in the US

A dedicated section of the report focuses on the expected market size of SYMDEKO for the United States. DelveInsight’s analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

What is SYMDEKO Prescribed for?

SYMDEKO is a prescribed medication designed to treat cystic fibrosis (CF) in individuals aged 6 years and older. It is intended for patients who possess two copies of the F508del mutation or have at least one mutation in the CF gene that responds positively to SYMDEKO treatment.

Why you should buy SYMDEKO Market Report:

The report provides future market assessments for SYMDEKO for Cystic Fibrosis in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts’ views, detailed overview of market competitors, and short analysis of other emerging therapies in U Cystic Fibrosis.
Leading Psilocybin for Cystic Fibrosis forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SYMDEKO
Discover the competitive landscape of SYMDEKO through 7MM
Get a Through Analysis of the SYMDEKO Development pipeline, Safety & Efficacy of the SYMDEKO, and ROA
Thorough SYMDEKO market forecast will help understand how drug is competing with other emerging SYMDEKO
Get analysis of the SYMDEKO clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Stay ahead in the competition by leveraging insights on the SYMDEKO market Report: Download the SYMDEKO Market Report

Related Reports

Cystic Fibrosis Market

DelveInsight’s Cystic fibrosis Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Cystic fibrosis Market.

Cystic Fibrosis Pipeline

“Cystic Fibrosis Pipeline Insights, 2024” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SYMDEKO Market Size expected to increase many folds by 2032, reports DelveInsight

ESKETAMINE DPI Market Size expected to increase many folds by 2032, reports DelveInsight

[Las Vegas, United States] (25 January 2024) The Latest report, ESKETAMINE DPI Market Size, Forecast, and Drug Insight 2032 is published by DelveInsight, a leader in healthcare research firm, providing insights into the ESKETAMINE DPI market landscape and market forecast of ESKETAMINE DPI up to 2032. This report is now available for review and analysis.

Are you interested in finding out the projected market size of ESKETAMINE DPI in 2032? Click @ ESKETAMINE DPI Market Size

The ESKETAMINE DPI Market Report offers projected sales forecasts for ESKETAMINE DPI for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products for Treatment Resistant Depression. It also covers analyst views along with market drivers and barriers.

Do you know your drug’s competitive positioning against ESKETAMINE DPI? Download Report: ESKETAMINE DPI Market Outlook

ESKETAMINE DPI is serving as a beacon of hope for the patients suffering from the Treatment Resistant Depression.

Esketamine has been given approval for individuals grappling with treatment-resistant depression. This implies that if you have tested at least two alternative antidepressants (each for a minimum of six weeks) and have not achieved remission or a minimum of a 50% enhancement in mood, esketamine could be a potential option for you.

The report extensively covers the details and developments related to ESKETAMINE DPI, capturing important highlights on the developmental pipeline, regulatory status and special designations of ESKETAMINE DPI, route of administration, safety and efficacy details.

ESKETAMINE DPI Market Assessment

This report provides a detailed market assessment of ESKETAMINE DPI for Treatment Resistant Depression in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

ESKETAMINE DPI Clinical Assessment

The report provides the clinical trials information of ESKETAMINE DPI for Treatment Resistant Depression covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.

ESKETAMINE DPI Competitive Landscape

ESKETAMINE DPI Market Size in the US

A dedicated section of the report focuses on the expected market size of ESKETAMINE DPI for the United States. DelveInsight’s analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

What is ESKETAMINE DPI Prescribed for?

Esketamine originates from a segment of the ketamine molecule,” explains Kaplin, a researcher with three years of experience studying the drug. “Due to its increased potency, it can be administered at a lower dosage, potentially minimizing side effects. With the FDA approval of an intranasal version, the likelihood of insurance companies covering this treatment has now increased.

Why you should buy ESKETAMINE DPI Market Report:

The report provides future market assessments for ESKETAMINE DPI for Treatment Resistant Depression in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts’ views, detailed overview of market competitors, and short analysis of other emerging therapies in Treatment Resistant Depression.
Leading ESKETAMINE DPI for Treatment Resistant Depression forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ESKETAMINE DPI.
Discover the competitive landscape of ESKETAMINE DPI through 7MM
Get a Thorough Analysis of the ESKETAMINE DPI Development pipeline, Safety & Efficacy of the ESKETAMINE DPI, and ROA
Thorough ESKETAMINE DPI market forecast will help understand how drug is competing with other emerging ESKETAMINE DPI
Get analysis of the ESKETAMINE DPI clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Stay ahead in the competition by leveraging insights on the ESKETAMINE DPI market Report: Download the ESKETAMINE DPI Market Report

Treatment resistant depression Market report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends in 7MM.

Treatment Resistant Depression Pipeline

Treatment Resistant Depression Pipeline Insights, 2024 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ESKETAMINE DPI Market Size expected to increase many folds by 2032, reports DelveInsight

GW Pharmaceutical/Jazz Pharmaceutical’s “Epidiolex (cannabidiol) market size expected to increase many folds by 2030, report DelveInsight

“Epidiolex (cannabidiol) market”

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Epidiolex (cannabidiol) (GW Pharmaceutical/Jazz Pharmaceutical) providing insights into the drug market landscape and market forecast of Epidiolex (cannabidiol) upto 2030. The report, titled “ Epidiolex (cannabidiol) – Market Size, Forecast, and Drug Insight – 2030″ is now available for review and analysis.

Are you interested in finding out the projected market size of Epidiolex (cannabidiol) in 2030? Click @ Epidiolex (cannabidiol) Market Size

The Epidiolex (cannabidiol) Market Report offers projected sales forecasts for Epidiolex (cannabidiol) for indications until 2030, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.

Epidiolex Overview:

GW Pharmaceutical/Jazz Pharmaceutical’s Epidiolex (cannabidiol) is serving as a beacon of hope for the patients suffering from the Epilepsy.

Epidiolex is a prescription medicine used to treat seizures in people with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.

Epidiolex is for use in adults and children who are at least 1 year old.

In April 2020, the U.S. Drug Enforcement Administration (DEA) announced the removal of cannabidiol from Schedule V of the Controlled Substances Act. Epidiolex is no longer considered a controlled substance.

The report extensively covers the details and developments related to Epidiolex (cannabidiol), capturing important highlights on developmental pipeline, regulatory status and special designations of Epidiolex (cannabidiol), route of administration, safety and efficacy details.

Do you know your drug’s competitive positioning against Epidiolex (cannabidiol)? Download Report @ Epidiolex (cannabidiol) Market Size

Epidiolex (cannabidiol) Market Assessment

This report provides a detailed market assessment of Epidiolex (cannabidiol) for Epilepsy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2030.

Epidiolex (cannabidiol) Clinical Assessment

The report provides the clinical trials information of Epidiolex (cannabidiol) for Epilepsy covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.

Epidiolex (cannabidiol) Competitive Landscape

Epidiolex (cannabidiol) Market Size in the US

A dedicated section of the report focuses on the expected market size of Epidiolex (cannabidiol) for the United States. DelveInsight’s analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

What is a Epidiolex (cannabidiol) Prescribed for?

Epidiolex (cannabidiol) is Prescribed for the treatment of seizures in people with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.

Key Highlights of Epidiolex (cannabidiol):

The report contains forecasted sales of Epidiolex (cannabidiol) for indication till 2030.
Comprehensive coverage of the late-stage emerging therapies for Epilepsy.
The report also features the qualitative and quantitative analysis with analysts as well as KOL views for Epidiolex (cannabidiol) in Epilepsy.

Request for Sample Report @ https://www.delveinsight.com/sample-request/epidiolex-cannabidiol-drug-insight-market-forecast

Why you should buy Epidiolex (cannabidiol) Market Report:

The report provides future market assessments for Epidiolex (cannabidiol) for Epilepsy in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts’ views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
Leading Epidiolex (cannabidiol) for Epilepsy forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Epidiolex (cannabidiol)
Discover the competitive landscape of Epidiolex (cannabidiol) through 7MM
Get a Thorough Analysis of the Epidiolex (cannabidiol) Development pipeline, Safety & Efficacy of the Epidiolex (cannabidiol), and ROA
Thorough Epidiolex (cannabidiol) market forecast will help understand how drug is competing with other emerging Epidiolex (cannabidiol)
Get analysis of the Epidiolex (cannabidiol) clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Related Reports By DelveInsight:

Epilepsy Pipeline

DelveInsight’s, “Epilepsy Pipeline Insight” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in Epilepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Top Services Offered By DelveInsight:

Unlock success with our Product Assessment case study. Gain valuable insights for strategic decision-making and product optimization in your industry. https://www.delveinsight.com/case-study/oncology-product-assessment-dashboard

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: GW Pharmaceutical/Jazz Pharmaceutical’s “Epidiolex (cannabidiol) market size expected to increase many folds by 2030, report DelveInsight

Merck’s Prevymis (letermovir) market size expected to increase many folds by 2030, report DelveInsight

“Prevymis (letermovir) market”

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Merck’s Prevymis (letermovir) providing insights into the drug market landscape and market forecast of Prevymis (letermovir) upto 2030. The report, titled “Prevymis (letermovir) – Market Size, Forecast, and Drug Insight – 2030” is now available for review and analysis.

Are you interested in finding out the projected market size of Prevymis (letermovir) in 2030? Click @ Prevymis (letermovir) market size

The Prevymis (letermovir) Market Report offers projected sales forecasts for Prevymis (letermovir) for indications until 2030, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.

Prevymis (letermovir) Overview

Merck’s Prevymis (letermovir) is serving as a beacon of hope for the patients suffering from the Cytomegalovirus (CMV) infection.

PREVYMIS is an antiviral agent that was initially approved by the FDA in 2017 for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). PREVYMIS is administered once-daily as an oral tablet or as an injection for intravenous infusion.

PREVYMIS is contraindicated in patients receiving pimozide or ergot alkaloids. Increased pimozide concentrations due to concomitant administration of PREVYMIS may lead to QT prolongation and torsades de pointes. Increased ergot alkaloids concentrations due to concomitant administration of PREVYMIS may lead to ergotism. PREVYMIS is contraindicated with pitavastatin and simvastatin when co-administered with cyclosporine. Significantly increased pitavastatin or simvastatin concentrations may lead to myopathy or rhabdomyolysis.

The report extensively covers the details and developments related to Prevymis (letermovir), capturing important highlights on developmental pipeline, regulatory status and special designations of Prevymis (letermovir), route of administration, safety and efficacy details.

Do you know your drug’s competitive positioning against Prevymis (letermovir)? Download Report : Prevymis (letermovir) market dynamics

Prevymis (letermovir) Market Assessment

This report provides a detailed market assessment of Prevymis (letermovir) for Cytomegalovirus (CMV) infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2030.

Prevymis (letermovir) Clinical Assessment

The report provides the clinical trials information of Prevymis (letermovir) for Cytomegalovirus (CMV) infection covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.

Prevymis (letermovir) Competitive Landscape

Prevymis (letermovir) Market Size in the US

A dedicated section of the report focuses on the expected market size of Prevymis (letermovir) for the United States. DelveInsight’s analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

What is a Prevymis (letermovir) Prescribed for?

Merck’s Prevymis (letermovir) is Prescribed for Cytomegalovirus (CMV) infection.

Key Highlights of Prevymis (letermovir):

The report contains forecasted sales of Prevymis (letermovir) for indication till 2030.
Comprehensive coverage of the late-stage emerging therapies for Cytomegalovirus (CMV) infection.
The report also features the qualitative and quantitative analysis with analysts as well as KOL views for Prevymis (letermovir) in Cytomegalovirus (CMV) infection.

Why you should buy Prevymis (letermovir) Market Report:

The report provides future market assessments for Prevymis (letermovir) for Cytomegalovirus (CMV) infection in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts’ views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
Leading Prevymis (letermovir) for Cytomegalovirus (CMV) infection forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Prevymis (letermovir)
Discover the competitive landscape of Prevymis (letermovir) through 7MM
Get a Through Analysis of the Prevymis (letermovir) Development pipeline, Safety & Efficacy of the Prevymis (letermovir), and ROA
Thorough Prevymis (letermovir) market forecast will help understand how drug is competing with other emerging Prevymis (letermovir)
Get analysis of the Prevymis (letermovir) clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Request for Sample Report @ https://www.delveinsight.com/sample-request/prevymis-letermovir-drug-insight-market-forecast

Related Reports By DelveInsight:

Cytomegalovirus (CMV) infection Market

DelveInsight’s “Cytomegalovirus (CMV) Infection Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Cytomegalovirus (CMV) Infection, historical and forecasted epidemiology as well as the Cytomegalovirus (CMV) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cytomegalovirus (CMV) infection Pipeline

DelveInsight’s, “Cytomegalovirus (CMV) infection Pipeline Insight” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Cytomegalovirus (CMV) infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Merck’s Prevymis (letermovir) market size expected to increase many folds by 2030, report DelveInsight

Advanced Driver Assistance Systems (ADAS) Market Size, Share, Trends & Global Forecast by 2030

“Attractive Opportunities in Advanced Driver Assistance Systems (ADAS) Market”

Advanced Driver Assistance Systems (ADAS) Market by System (ACC, DMS, IPA, PDS< TJA, FCW,, RSR, LDW, AEB, BSD), Component (Camera, LiDAR, Ultrasonic, Radar), Vehicle Type, EV Type, Vehicle Class, Level of Autonomy, Offering, Sales Channel and Region - Global Forecast to 2030

The ADAS market is projected to grow from USD 30.9 billion in 2022 to USD 65.1 billion by 2030, registering a CAGR of 9.7%.

The demand for Advanced Driver Assistance Systems (ADAS) is increasing quickly due to the rise in traffic accidents on a global scale. To make driving safer and cut down on accidents, automakers are heavily investing in the development of these technologies. Customers are increasingly choosing vehicles with ADAS capabilities as they become more aware of the safety advantages of these systems. The need for ADAS is being further increased by governments drafting legislation to make such systems required in vehicles.

L1 autonomy level to be the largest market during forecast period

Level 1 is the lowest level of autonomous driving defined by the Society of Automotive Engineers (SAE). An L1 vehicle can handle either steering or control the speed, not at the same time. The driver controls most of the driving tasks, and the driver assistance system helps the driver with tasks such as lane departure warnings. ADAS features such as adaptive cruise control, lane departure warning, tire pressure monitoring systems, and adaptive front lights are considered under level 1 driving systems. As of 2022, many higher-end mid-tier passenger and luxury vehicles have level 1 autonomous features. Mercedes (Germany), for instance, since 2018 provides level 1 autonomous for its S-class passenger car. Similarly, Toyota’s RAV4 has level 1 autonomous features in its 2022 model. Cars such as Jeep Wrangler 4Xe, Renault Arkana, and Nissan Qashqai are also available with level 1 autonomous systems.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1201

Software to be the fastest growing segment during the forecast period

Increasing demand for accurate and faster object recognition will be a major growth driver for the software segment of the ADAS market. Modern vehicles are equipped with high-resolution cameras and long-range radar sensors for driver assistance. Hence, developments in image recognition technology will play a critical role in deploying these sensors in upcoming vehicles. Newer features such as pedestrian recognition, cyclist recognition, vehicle detection, driver monitoring systems, and traffic sign recognition are being tested, and plans to roll them out in more vehicles for improved occupant safety are underway. More sophisticated ADAS features would demand faster and more accurate software algorithms/platforms for detecting objects with low latency. BlackBerry (Canada) has developed QNX as a modular, flexible, and hardware-optimized software platform for ADAS applications. ADAS software consists of algorithms that perform pre-decided functions based on the input data from cameras, radar, LiDAR, and ultrasonic sensors. The input data is processed by the ECUs and activates the physical vehicle components such as steering, brakes, throttle, and others to evade accidents. The entire process is controlled and monitored by the software platform, from analyzing the input data to the decision-making. Automakers are turning toward deep learning as they look for innovative ways to enable smart camera applications and automated driving systems for next-generation vehicles. In December 2020, Renesas Electronics (Japan) developed an R-car software development kit. This complete software platform enables quick and easy software development and offers validation for smart cameras and automated driving applications used in commercial, passenger, and off-road vehicles. It manages the software complexity and supporting features ranging from entry safety compliance to advanced highway pilot.

“Europe is leading the ADAS market as of 2022”

Automotive is one of the key industries in Europe. In June 2022, the region had 301 automobile assembly and production plants, of which 134 produce passenger cars, 41 produce vans, 52 build trucks, 66 produce buses, 72 make engines, and 18 make batteries. According to the European Automobile Manufacturers Association (ACEA), Europe accounted for around 22% of global vehicle production in 2022. The European automotive market registered steady growth in the last six years despite the recent global automotive slowdown. Leading European automotive manufacturers to offer high-performance engines and advanced safety features to stay competitive. Passenger car sales of major automakers such as the Volkswagen Group, Mercedes Benz, Renault, Hyundai, BMW, Toyota, and Stellantis led to the demand for ADAS-enabled vehicles in the region.

According to experts, stringent emission regulations and zero emission targets in Europe would majorly affect both passenger car and commercial vehicle manufacturers during the forecast period. The growth of the European ADAS market can be attributed to technological advancements in driver assistance features such as traffic jam assist and blind-spot detection with rear cross-traffic and mandates that have been set up since July 2022 or features such as DMS, AEB and LCW in passenger cars. The growing shift to EVs and the growing demand for road safety will increase ADAS demand in the region.

Key Market Players:

The ADAS market is dominated by established players such as Robert Bosch (Germany), Denso (Japan), Continental AG (Germany), Magna International (US), and ZF Friedrichshafen (Germany), among others. These companies provide ADAS components to global OEMs. These companies have set up R&D infrastructure and offer best-in-class products to their customers.

Request Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=1201

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/driver-assistance-systems-market-1201.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Driver Assistance Systems (ADAS) Market Size, Share, Trends & Global Forecast by 2030

Powerful Anthology “Even the Shadows Had Shadows” Illuminates Falklands War Through Unspoken Conversations

Jan 25, 2024 – Today, we are thrilled to announce the release of “Even the Shadows Had Shadows,” a compelling anthology co-authored by Steve Butterworth and Phyllis Wiggins. This poignant collection of poems and reflections unveils the unspoken conversations of those directly involved in the Falklands Campaign of 1982 – the combatants, their families, and the resilient islanders.

The Falklands War, a chapter in history etched with the indelible marks of sacrifice and trauma, is vividly brought to life through the artistry of words. Drawing inspiration from the likes of Siegfried Sassoon, Wilfred Owen, and contemporary poets like William Erhart, “Even the Shadows Had Shadows” follows a longstanding tradition of using poetry as a medium to communicate the harrowing experiences of war.

Authors’ Background:

Steve Butterworth, a common northern boy turned Royal Navy serviceman, discovered the seed for this anthology in a heartfelt poem written by his late mother, Barbara, during his deployment in the Falklands. Phyllis Wiggins, a prominent figure in the Falkland Veterans community, lent her expertise to compile and format this extraordinary collection, drawing attention to the emotional landscapes of veterans and their families.

Foreword by Dr. David Jackson:

Former Royal Marine and Falklands Veteran Dr. David Jackson provides a thought-provoking foreword. He reflects on the historical connection between poetry and war, emphasizing its role in processing the burdens that linger long after the conflicts end. Dr. Jackson underscores the courage contributors require to share their experiences and invites readers to engage empathetically with the profound narratives within the book.

A Humanitarian Pilgrimage:

The book recounts a transformative journey in 2022 when a Falklands Veteran boarded a plane to Buenos Aires. In four decades, this marked the first joint gathering of UK and Argentine Falkland Veterans. The narrative details the emotional encounters, shared stories, and reconciliations that transpired during this historic event, shedding light on the common threads that bind the human experience across borders.

Key Themes Explored:

The anthology delves into the complexities of war, exploring themes of loss, forgiveness, and the enduring impact on both British and Argentine veterans. It also addresses controversial issues, such as the Argentine war graves in the Falklands and the post-war challenges faced by the Argentine veterans.

Closing Thoughts:

“Even the Shadows Had Shadows” serves as a testament to the healing power of shared narratives and the capacity for understanding that transcends borders. The book invites readers to witness the unspoken conversations, acknowledging the lasting impact of war on individuals and communities.

About the Authors

Steve Butterworth: A true northern spirit, Steve Butterworth’s journey from a Lancashire mill town to the decks of HMS Intrepid in the South Atlantic reflects the choices faced by many in the 1970s. Opting for adventure over the confines of factories, Steve embarked on a stint aboard the carrier HMS Hermes before the harsh realities of war in the Falklands Campaign. The genesis of “Even the Shadows Had Shadows” occurred when Steve discovered a poignant poem by his late mother, Barbara, offering a unique and intimate perspective of a mother’s love during his service. Motivated by the need to document personal experiences, Steve initiated a Facebook group that evolved into this deeply moving archive, capturing the emotions and reflections of those connected to the Falklands Conflict of ’82.

Phyllis Wiggins: The driving force behind the compilation and formatting of “Even the Shadows Had Shadows,” Phyllis Wiggins is a revered figure in the Falkland Veterans community. Known for her tireless charity work, Phyllis has raised substantial funds for military and civilian causes, embodying dedication beyond expectations. Balancing her commitments, Phyllis manages family life with her husband Jim, a Royal Marine veteran. Her involvement in the book has garnered admiration from peers like Falkland veteran Charlie McColgan, who aptly describes her as a superstar. Phyllis brings expertise and compassion to this anthology, elevating its impact and resonance within the military veteran community.

Book Name: Even the Shadows Had Shadows
Author Name: Steve Butterworth
ISBN Number: 1916964680
Paperback Version: Click Here
Hardcover Version: Click Here

Media Contact
Company Name: Amazon Publishing Company
Email: Send Email
Phone: +1-877-311-2129
Country: United States
Website: https://amzpublishingcompany.com/